Get the Stockscreener App
0.9764
5.20%
-0.0536
Pre-market:
.95
-0.0264
-2.70%
Longeveron Inc stock is traded at $0.9764, with a volume of 541.30K.
It is down -5.20% in the last 24 hours and up +2.41% over the past month.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
See More
Previous Close:
$1.03
Open:
$1.03
24h Volume:
541.30K
Relative Volume:
0.10
Market Cap:
$28.59M
Revenue:
$1.20M
Net Income/Loss:
$-22.70M
P/E Ratio:
-0.7508
EPS:
-1.3005
Net Cash Flow:
$-19.24M
1W Performance:
-11.24%
1M Performance:
+2.41%
6M Performance:
+14.87%
1Y Performance:
-39.35%
1-Day Range:
$0.925
$1.03
1-Week Range:
$0.925
$1.14
52-Week Range:
$0.475
$1.83
Longeveron Inc Stock (LGVN) Company Profile
Name
Longeveron Inc
Sector
Industry
Phone
305-302-7158
Address
1951 NW 7TH AVENUE, MIAMI
Compare LGVN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
0.9764 | 28.59M | 1.20M | -22.70M | -19.24M | -1.3005 |
VRTX
Vertex Pharmaceuticals Inc
|
435.10 | 110.67B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
766.02 | 80.98B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
787.95 | 49.00B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.79 | 41.87B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
299.81 | 33.28B | 5.36B | 287.73M | 924.18M | 2.5229 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
Longeveron Inc Stock (LGVN) Latest News
The Longevity Trade Is No Longer a Buzzword — It's a $120 - GlobeNewswire
Longeveron | EFFECT: Others - Moomoo
Longeveron (LGVN) Stock Good Till Cancel (Bearish Sentiment) 2026-04-20Expert Breakout Alerts - Cổng thông tin điện tử tỉnh Lào Cai
[EFFECT] Longeveron Inc. SEC Filing - Stock Titan
30.9M Longeveron shares registered for resale (NASDAQ: LGVN) - Stock Titan
LGVN Stock Price, Quote & Chart | LONGEVERON INC-A (NASDAQ:LGVN) - ChartMill
Longeveron Restores Executive Pay After Recent Financing - TipRanks
What is the long-term potential of Longeveron (LGVN) Stock | LGVN Q4 Earnings: Beats Estimates by $0.19Core Business Growth - Cổng thông tin điện tử tỉnh Tây Ninh
Longeveron Inc. Files Form 8-K Current Report with SEC – Company Details and Stock Information (2026) - Minichart
Aug Setups: Is Longeveron Inc stock a value trapMarket Growth Summary & Safe Capital Allocation Plans - baoquankhu1.vn
Longeveron restores executive pay, approves new stock unit grants following financing By Investing.com - Investing.com South Africa
Longeveron restores executive pay, approves new stock unit grants following financing - Investing.com
Longeveron IncRepaid Executives For Compensation Reductions Following FinancingSEC Filing - TradingView
Longeveron grants RSUs to executives after restoring reduced pay - TradingView — Track All Markets
Longeveron (NASDAQ: LGVN) restores pay and grants RSUs after financing - Stock Titan
Longeveron Prospectus Filed For Resale Of Up To 30.9 Million Class A Common Shares By Selling Stockholders- SEC Filing - TradingView
Longeveron (NASDAQ: LGVN) resale filing details 30.9M registered shares - Stock Titan
Biotechs Racing to Translate Longevity Science Into Real Therapies — And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells - Cantech Letter
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells - Finansavisen
IPO Launch: What is Longeveron Incs book value per share2026 Earnings Impact & Weekly Chart Analysis and Guides - baoquankhu1.vn
Longeveron receives China patent for stem cell potency assay By Investing.com - Investing.com Canada
Longeveron receives China patent for stem cell potency assay - Investing.com
Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) - The Manila Times
China grants Longeveron stem cell patent rights running through 2041 - Stock Titan
Is Longeveron (LGVN) Stock trading below intrinsic value | Price at $1.07, Down 7.33%High Volume Stocks - Xã Thanh Hà
Risk Check: Is Longeveron Inc stock good for income investors2026 Summary & Verified Short-Term Plans - baoquankhu1.vn
Market Outlook: Whats Longeveron Incs historical return2026 Opening Moves & Weekly High Return Opportunities - baoquankhu1.vn
Investment Review: Is Longeveron Inc exposed to currency risksEarnings Trend Report & Step-by-Step Trade Execution Guides - baoquankhu1.vn
LGVN Technical Analysis & Stock Price Forecast - Intellectia AI
[Form 4] Longeveron Inc. Insider Trading Activity - Stock Titan
Longeveron (LGVN) CMO has shares withheld to cover RSU tax obligations - Stock Titan
Longeveron (LGVN) CFO has 13,145 shares withheld to cover RSU tax - Stock Titan
Longeveron (LGVN) CEO has shares withheld to cover RSU tax bill - Stock Titan
Longeveron (NASDAQ: LGVN) CTO reports RSU tax-withholding of 8,633 shares - Stock Titan
Longeveron | 4: Statement of changes in beneficial ownership of securities-Officer Willard Stephen H - Moomoo
Patterns Watch: Can Longeveron Inc outperform in the next rallyEarnings Recap Summary & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
LGVN Stock Chart | LONGEVERON INC-A (NASDAQ:LGVN) - ChartMill
LGVN: Laromestrocel shows strong clinical progress and regulatory momentum across multiple indications - TradingView
Movement Recap: How cyclical is Longeveron Incs revenue stream2026 PreEarnings & Entry and Exit Point Strategies - baoquankhu1.vn
Is Longeveron Inc stock good for income investorsTrade Entry Summary & Target Return Focused Picks - baoquankhu1.vn
Moving Averages: Will Longeveron Inc stock hit new highs in YEAR2026 Rallies & Step-by-Step Trade Execution Guides - baoquankhu1.vn
(LGVN.O) | Stock Price & Latest News - Reuters
Profit Review: Can Longeveron Inc outperform in the next rally2026 Major Catalysts & Reliable Price Breakout Alerts - baoquankhu1.vn
Longeveron Receives Extended Nasdaq Compliance Grace Period - tipranks.com
Longeveron Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView — Track All Markets
Longeveron (NASDAQ: LGVN) granted more time to cure Nasdaq $1 bid rule - Stock Titan
Longeveron | 8-K: Current report - Moomoo
Longeveron braces for Q4 results following recent funding boost - MSN
Longeveron Cancels Special Meeting, Reschedules Reverse Split Vote - TipRanks
Longeveron (NASDAQ: LGVN) shifts reverse split proposal to annual - Stock Titan
Longeveron Inc. (NASDAQ:LGVN) Q4 2025 earnings call transcript - MSN
Longeveron Inc Stock (LGVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Longeveron Inc Stock (LGVN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Soffer Rock | Director |
May 29 '25 |
Sale |
1.30 |
10,000 |
13,000 |
220,034 |
4.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):